Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 3/2021

01-10-2021 | Phlebothrombosis

Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE)

Authors: Xin Zhang, Qiyan Cai, Xiaohui Wang, Ke Liao, Changchun Hu, Hong Chen

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2021

Login to get access

Abstract

Venous thromboembolism (VTE), which is characterized by pulmonary embolism and deep vein thrombosis, has become a serious public concern. Notably, over half of the patients with VTE are over 70 years of age, but elderly patients are at high risk of anti-coagulation and bleeding, which increase with age. Moreover, risk factors and frailty also show a difference between elderly patients and ordinary patients diagnosed with VTE. Rivaroxaban is a direct inhibitor of activated factor Xa and has the advantage of predictable pharmacodynamics and pharmacokinetics, no coagulation monitoring, and few drug interactions. As a first-line therapy for VTE, this drug is more advantageous than traditional therapy and exhibits good efficacy and safety for ordinary patients. However, the effectiveness and safety of rivaroxaban in elderly patients have not been fully elucidated. This article reviewed the use of rivaroxaban in elderly patients, including drug interactions, monitoring, reversal agents of rivaroxaban, and the use of small dosages of rivaroxaban in elderly patients.
Literature
1.
Engbers MJ, van Hylckama Vlieg A, Rosendaal FR (2010) Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 10:2105–2112CrossRef
2.
Sharma M, Cornelius VR, Patel JP et al (2015) Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 132:194–204PubMedPubMedCentralCrossRef
3.
Karamichalakis N, Georgopoulos S, Vlachos K et al (2016) Efficacy and safety of novel anticoagulants in the elderly. J Geriatr Cardiol 13:718–723PubMedPubMedCentral
4.
5.
6.
Scaglione F (2013) New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 52:69–82PubMedCrossRef
7.
Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW (1992) Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339:441–445PubMedCrossRef
8.
Columbus I, Büller HR, Gent M, Gallus AS, Ginsberg J, Prins MH, Baildon R (1997) Low-molecular-weight heparin in the treatment of patients with venous thromboem-bolism. N Engl J Med 337:657–662CrossRef
9.
Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE et al (2013) Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thrombo-embolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 11:21PubMedPubMedCentralCrossRef
10.
Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM (2012) Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 130:956–966PubMedCrossRef
11.
Favaloro EJ, Bonar R, Butler J, Marsden K (2013) Laboratory testing for the new oral anticoagulants: a review of current practice. Pathology 45:435–437PubMedCrossRef
12.
Di Minno A, Spadarella G, Prisco D, Franchini M, Lupoli R, Di Minno MN (2013) Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. Semin Thromb Hemost 39:840–846PubMedCrossRef
13.
DeWald TA, Becker RC (2014) The pharmacology of novel oral anticoagulants. J Thromb Thrombolysis 37:217–233PubMedCrossRef
14.
Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M (2014) Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35:3033–3069, 3069a-3069PubMedCrossRef
15.
Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939–an oral, direct Factor Xa inhibitor–after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873–880CrossRefPubMed
16.
The EINSTEIN Investigators (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510CrossRef
17.
The EINSTEIN–PE Investigators (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297CrossRef
18.
International Conference on Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) (1994) Topic E7 Note for Guidance on Studies to Support of Special Populations: Geriatrics, CPMP/ICH/379/95. London: European Medicine Agency
19.
Johnson SA, Eleazer GP, Rondina MT (2016) Pathogenesis, diagnosis, and treatment of venous thromboembolism in older adults. J Am Geriatrics Soc 64(9):1869–1878CrossRef
20.
Weill-Engerer S, Meaume S, Lahlou A, Piette F, Saint-Jean O, Sachet A, Beinis JY, Gallinari C, Grancher AS, Vincent JP, Naga H, Belmin J, Salvatore R, Kazes M, Pautas E, Boiffin A, Piera JB, Duviquet M, Knafo D, Piau A et al (2004) Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc 52:1299–1304PubMedCrossRef
21.
Gaber TA (2005) Significant reduction of the risk of venous thromboembolism in all long-term immobile patients a few months after the onset of immobility. Med Hypotheses 64:1173–1176PubMedCrossRef
22.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, Fallon O, WM, Melton LJ III (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160:809–815PubMedCrossRef
23.
Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715–722PubMedCrossRef
24.
Howell MD, Geraci JM, Knowlton AA (2001) Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, casecontrol study. J Clin Epidemiol 54:810–816PubMedCrossRef
25.
Yang CC, Kao CC (2007) Cardiovascular diseases and the risk of venous thromboembolism: a hospital-based case-control study. J Chin Med Assoc 70:103–109PubMedCrossRef
26.
Sellier E, Labarere J, Sevestre MA, Belmin J, Thiel H, Couturier P, Bosson JL (2008) Risk factors for deep vein thrombosis in older patients: a multicenter study with systematic compression ultrasonography in postacute care facilities in France. J Am Geriatr Soc 56:224–230PubMedCrossRef
27.
Kamphuisen PW, Agnelli G, Sebastianelli M (2005) Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost 3:1187–1194PubMedCrossRef
28.
Kelly J, Rudd A, Lewis R, Hunt BJ (2001) Venous thromboembolism after acute stroke. Stroke 32:262–267PubMedCrossRef
29.
Erelel M, Cuhadaroglu C, Ece T, Arseven O (2002) The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med 96:515–518PubMedCrossRef
30.
Lesser BA, LeeperKV Jr, Stein PD, SaltzmanHA, Chen J, Thompson BT, Hales CA, Popovich J Jr (1992) Greenspan RH,Weg JG. The diagnosis of acute pulmonary embolism in patients with chronic obstructive pulmonary disease. Chest 102:17–22PubMedCrossRef
31.
Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW (2008) Cardiovascular risk factors and venous thromboembolism: a metaanalysis. Circulation 117:93–102PubMedCrossRef
32.
Prandoni P (2009) Venous and arterial thrombosis: two aspects of the same disease? Eur J Intern Med 20:660–661PubMedCrossRef
33.
Song Z-K, Cao H, Wu H, Wei Q, Tang M, Yang S, Liu Y, Qin L (2020) Current status of rivaroxaban in elderly patients with pulmonary embolism. Exp Ther Med 19(4):2817–2825PubMedPubMedCentral
34.
Gary T, Hafner F, Froehlich H et al (2010) High factor VIII activity, high plasminogen activator inhibitor 1 antigen levels and low factor XII activity contribute to a thrombophilic tendency in elderly venous thromboembolism patients. Acta Haematol 124(4):214–217PubMedCrossRef
35.
Crous-Bou M, Harrington L, Kabrhel C (2016) Environmental and genetic risk factors associated with venous thromboembolism. Semin Thromb Hemostasis 8:808–820CrossRef
36.
Folsom AR, Cushman M, Tsai MY, Heckbert SR, Aleksic N (2002) Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am J Hematol 71:285–290PubMedCrossRef
37.
Ridker PM, Hennekens CH, Miletich JP (1999) G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 99:999–1004PubMedCrossRef
38.
Morley JE, Vellas B, van Kan G, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarter RJ, Gutierrez RLM, Rockwood K, von Haehling S, Vandewoude MF, Walston J (2013) Frailty consensus: a call to action. J Am Med Direct Assoc 14(6):392–397CrossRef
39.
Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol Biol Med Sci 56:M146–M156CrossRef
40.
Collard RM, Boter H, Schoevers RA, Oude Voshaar RC (2012) Prevalence of frailty in communitydwelling older persons: a systematic review. J Am Geriatr Soc 60:1487–1492PubMedCrossRef
41.
Ho P, La Brooy B, Hayes L, Lim WK (2015) Direct oral anticoagulants in frail older adults: a geriatric perspective. Semin Thromb Hemostasis 41(4):389–394CrossRef
42.
Wehinger C, Stollberger C, Langer T, Schneider B, Finsterer J (2001) Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke 32:2246–2252PubMedCrossRef
43.
Donze J, Clair C, Hug B et al (2012) Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 125:773–778PubMedCrossRef
44.
Abdelhafiz AH, Wheeldon NM (2008) Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. Am J Geriatr Pharmacother 6:1–11PubMedCrossRef
45.
Coleman CI, Turpie AG, Bunz TJ, Beyer-Westendorf J (2018) Effectiveness and safety of rivaroxaban versus warfarin in frail patients with venous thromboembolism. Am J Med 131(8):933–938PubMedCrossRef
46.
Verhamme P, Bounameaux H (2014) Direct oral anticoagulants for acute venous thromboembolism: closing the circle? Circulation 129:725–727PubMedCrossRef
47.
Larsson L, Grimby G, Karlsson J (1979) Muscle strength and speed of movement in relation to age and muscle morphology. J Appl Physiol 46:451–456PubMedCrossRef
48.
Migliacci R, Becattini C, Pesavento R, Davi G, Vedovati MC, GuglielminiG, Falcinelli E, Ciabattoni G, Dalla VF, Prandoni P, Agnelli G, Gresele P (2007) Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica 92:812–818PubMedCrossRef
49.
Chopard RP, Miranda Neto MH, Biazotto W, Molinari SL (1994) Agerelated changes in the human renal veins and their valves. Ital J Anat Embryol 99:91–101PubMed
50.
Brooks EG, Trotman W, Wadsworth MP, Taatjes DJ, Evans MF, Ittleman FP, Callas PW, Esmon CT, Bovill EG (2009) Valves of the deep venous system: an overlooked risk factor. Blood 114:1276–1279PubMedPubMedCentralCrossRef
51.
Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B (2006) Chronic venous disease. N Engl J Med 355:488–498PubMedCrossRef
52.
Buller HR (2012) Oral rivaroxaban for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies. Blood 120(21):20–20CrossRef
53.
Sato D, Ikeda S, Koga S et al (2018) Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age. Heart Vessels 34:678–687PubMedCrossRef
54.
Zhou H, Wei Q, Wu H et al (2019) Efficacy of low-dose rivaroxaban in an 88-year-old female with pulmonary embolism: a case report. Medicine 98(20):e15705PubMedPubMedCentralCrossRef
55.
Menichetti M, Rosso S, Menegatti E et al (2015) Use of rivaroxaban in an elderly patient with intermediate-low early mortality risk due to pulmonary embolism: a case report. J Med Case Rep 9(1):274PubMedPubMedCentralCrossRef
56.
Xarelto® [package insert] (2017) Janssen Pharmaceuticals Inc., Titusville
57.
Rahimi R, Abdollahi M (2012) An update on the ability of St. John’s wort to affect the metabolism of other drugs. Exp Opin Drug Metab Toxicol 8:691–708CrossRef
58.
Hennessy M, Kelleher D, Spiers JP et al (2002) St John’s wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 53:75–82PubMedPubMedCentralCrossRef
59.
Nutescu E, Chuatrisorn I, Hellenbart E (2011) Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 31:326–323PubMedCrossRef
60.
Gnoth MJ, Buetehorn U, Muenster U et al (2011) In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 338:372–380PubMedCrossRef
61.
Yasaka M, Lip GY (2014) Impact of non-vitamin k antagonist oral anticoagulants on intracranial bleeding in Asian patients with non-valvular atrial fibrillation. Circ J 78:2367–2372PubMedCrossRef
62.
Repplinger DJ, Hoffman RS, Nelson LS, Hines EQ, Howland M, Su MK (2016) Lack of significant bleeding despite large acute rivaroxaban overdose confirmed with whole blood concentrations. Clin Toxicol 54:647–649CrossRef
63.
Spiller HA, Mowry JB, Aleguas A, Griffith JR, Goetz R, Ryan ML, Bangh S, Klein-Schwartz W, Schaeffer S, Casavant MJ (2016) An observational study of the factor Xa inhibitors rivaroxaban and apixaban as reported to eight poison centers. Ann Emerg Med 67:189–195PubMedCrossRef
64.
Cuker A, Siegal DM, Crowther MA et al (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64(11):1128–1139PubMedPubMedCentralCrossRef
65.
Helin TA, Pakkanen A, Lassila R et al (2013) Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem 59:807–814PubMedCrossRef
66.
Hillarp A, Baghaei F, Fagerberg Blixter I et al (2011) Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 9:133–139PubMedCrossRef
67.
Molenaar PJ, Dinkelaar J, Leyte A (2012) Measuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 50:1799–1807PubMedCrossRef
68.
Freyburger G, Macouillard G, Labrouche S et al (2011) Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 127:457–465PubMedCrossRef
69.
Asmis LM, Alberio L, Angelillo-Scherrer A et al (2012) Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 129:492–498PubMedCrossRef
70.
Mani H, Rohde G, Stratmann G et al (2012) Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 108:191–198PubMedCrossRef
71.
Douxfils J, Tamigniau A, Chatelain B et al (2013) Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 110:723–731PubMedCrossRef
72.
Samama MM, Guinet C, Le Flem L et al (2013) Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis 35:140–146PubMedCrossRef
73.
Samama MM, Contant G, Spiro TE et al (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107:379–387PubMedCrossRef
74.
Lu G, Lin J, Curnutte JT, Conley PB (2016) Andexanet alfa, a universal antidote under development for factor Xa inhibitors, reverses rivaroxaban-induced inhibition of thrombin generation initiated by the intrinsic coagulation pathway independent of TFPI. Presented at the American Society of Hematology 58th Annual Meeting, San Diego, CA, December 3–6 2016
75.
Lu G, Lin J, Coffey G, Curnutte JT, Conley PB (2015) Interaction of andexanet alfa, a universal antidote to fXA inhibitors, with tissue factor pathway inhibitor enhances reversal of fXA inhibitor-induced anticoagulation. J Thromb Haemost 13:634–635
76.
Crowther M, Gallia L, Genmin L et al (2014) A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Blood 124:A4269CrossRef
77.
Crowther M, Kitt M, Lorenz T et al (2013) A phase 2 randomized, doubleblind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemost 11(suppl 2):201
78.
Crowther M, Vandana M, Kitt M et al (2013) A phase 2 randomized, double-blind, placebo- controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for fXa inhibitors. Blood 122:A3636CrossRef
79.
Crowther M, Lu G, Conley P et al (2014) Sustained reversal of apixaban anticoagulation with andexanet alfa using a bolus plus infusion regimen in a phase 2 placebo controlled trial. Eur Heart J 35(suppl 1):P738
80.
Crowther M, Levy G, Lu G et al (2014) Reversal of enoxaparin-induced anticoagu-lation in healthy subjects by andexanet alfa (PRT064445), an antidote for direct and indirect fXa inhibitors—a phase 2 randomized, double-blind, placebo-controlled trial. J Thromb Haemost 12(suppl 1):A1
81.
Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413–2424PubMedCrossRef
82.
ClinicalTrials.gov. A study in patients with acute major bleeding to evaluate the ability of andexanet alfa to reverse the anticoagulation effect of direct and indirect oral anticoagulants. Accessed 29 Feb 2016
83.
Cuker A, Burnett A, Triller D et al (2019) Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. Am J Hematol 94:697–709PubMedCrossRef
84.
January CT, Wann LS, Calkins H et al (2019) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 74:104–132PubMedCrossRef
85.
Lip GYH, Banerjee A, Boriani G, Chiang C et al (2018) Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report. Chest 154:1121–1201PubMedCrossRef
86.
Connolly SJ, Crowther M, Eikelboom JW et al (2019) Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 380:1326–1335PubMedPubMedCentralCrossRef
87.
Smith MN, Deloney L, Carter C et al (2019) Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. J Thromb Thromb 48(2):250–255CrossRef
88.
Sullivan DW Jr, Gad SC, Laulicht B et al (2015) Nonclinical Safety Assessment of PER977: a small molecule reversal agent for new oral anticoagulants and heparins. Int J Toxicol 34:308–317PubMedCrossRef
89.
Ansell JE, Bakhru SH, Laulicht BE et al (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371:2141–2142PubMedCrossRef
90.
91.
Goodnough LT, Levy JH (2016) The judicious use of recombinant factor VIIa. Semin Thromb Hemost 42:125–132PubMedCrossRef
92.
Perzborn E, Heitmeier S, Laux V, Buchmuller A (2014) Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res 133:671–681PubMedCrossRef
93.
Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T (2012) Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 107:253–259PubMedCrossRef
94.
Halim AB, Samama MM, Mendell J (2014) Ex vivo reversal of the anticoagulant effects of edoxaban. Thromb Res 134:909–913PubMedCrossRef
Metadata
Title
Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE)
Authors
Xin Zhang
Qiyan Cai
Xiaohui Wang
Ke Liao
Changchun Hu
Hong Chen
Publication date
01-10-2021
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-021-02415-5

Other articles of this Issue 3/2021

Journal of Thrombosis and Thrombolysis 3/2021 Go to the issue

OriginalPaper

Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure

Correction

Correction to: Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation

OriginalPaper

Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis

OriginalPaper

The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials

BriefCommunication

A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer

BriefCommunication

Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits